Search

Your search keyword '"Remission status"' showing total 4 results
Start Over Descriptor "Remission status" Topic bone marrow
4 results on '"Remission status"'

2. Does day 14 bone marrow status predict response to chemotherapy in acute myeloid leukemia? Experience of a hemato-oncology care center from Eastern India.

Author

Nataraj, K, Mandal, Prakas, Ghosh, Malay, and Bhattacharyya, Maitreyee

Subjects
*ACUTE myeloid leukemia, *BONE marrow, *FORECASTING, *ACUTE leukemia, *SURVIVAL analysis (Biometry), BONE marrow examination
Abstract

Background: Acute myeloid leukemia (AML), the most common type of acute leukemia in adults, yet continues to have the lowest survival rate of all leukemias. The present study aimed to study ability of Day 14 marrow status to predict the remission status in AML. Materials and Methods: This prospective, observational study conducted in 30 AML patients who received "induction remission" as per standard guidelines and undergone bone marrow (BM) aspiration and biopsy on day 14 and day 28. Complete remission (CR) defined as per standard criteria. SPSS 15.3 was used to perform statistical analysis. Results: Median BM blast count on day14 was 10.6% (range, 1–50). Patients achieving remission in day 28 + BM had mean day 14 BM blast count of 8.52% compared to 21.00% in those who did not achieve remission. Majority (90.9%) of the patients with ≤15% BM blast on D14 was in remission. Comparing D14 BM blast% with CR, blast >15% cut off (across all the cut offs, i.e., 5%, 10%, 15%, or 20%) was the best to find those who entered remission; but the negative predictive value (NPV) was poor across all groups. Conclusions: There is a trend toward early relapse in patients with higher blast on D14. However, D14 BM marrow blast >15% has a poor NPV for predicting relapse. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

3. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China

Author

Zhen-Yang Gu, Yu-Jun Dong, Xiao-Rui Fu, Nai-Nong Li, Yao Liu, Xiao-Xiong Wu, Yi-Ni Wang, Yu-Hang Li, Han-Yun Ren, Ming-Zhi Zhang, Xiao-Fan Li, Mai-Hong Wang, Ya-Mei Wu, Dai-Hong Liu, Zhao Wang, Liang-Ding Hu, Wen-Rong Huang, and Peng Lyu

Subjects
medicine.medical_specialty, China, medicine.medical_treatment, Auto-HSCT, chemical and pharmacologic phenomena, Hematopoietic stem cell transplantation, Allo-HSCT, Gastroenterology, Transplantation, Autologous, immune system diseases, Internal medicine, hemic and lymphatic diseases, medicine, Humans, Transplantation, Homologous, Remission status, Stage (cooking), Retrospective Studies, business.industry, Mortality rate, Hematopoietic Stem Cell Transplantation, Peripheral T-cell lymphoma, Lymphoma, T-Cell, Peripheral, Retrospective cohort study, General Medicine, Original Articles, medicine.disease, Lymphoma, Transplantation, PIT score, medicine.anatomical_structure, Treatment Outcome, surgical procedures, operative, Medicine, Bone marrow, Neoplasm Recurrence, Local, business, therapeutics
Abstract

Background:. There were few studies on real-world data about autologous hematopoietic stem cell transplantation (auto-HSCT) or allogeneic HSCT (allo-HSCT) in peripheral T-cell lymphoma (PTCL). This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-HSCT in China. Methods:. From July 2007 to June 2017, a total of 128 patients who received auto-HSCT (n = 72) or allo-HSCT (n = 56) at eight medical centers across China were included in this study. We retrospectively collected their demographic and clinical data and compared the clinical outcomes between groups. Results:. Patients receiving allo-HSCT were more likely to be diagnosed with stage III or IV disease (95% vs. 82%, P = 0.027), bone marrow involvement (42% vs. 15%, P = 0.001), chemotherapy-resistant disease (41% vs. 8%, P = 0.001), and progression disease (32% vs. 4%, P

Published
2021
Full Text
View/download PDF

4. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value

Author

Ana Garrido, Jorge Sierra, Marta Pratcorona, Maite Carricondo, Rodrigo Martino, Salut Brunet, Albert Esquirol, Josep F. Nomdedeu, Miguel Ángel Rubio, Montserrat Hoyos, Elena Bussaglia, Irene García-Cadenas, and Camino Estivill

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Myeloid, Neoplasm, Residual, Time Factors, Adolescent, medicine.medical_treatment, Hematopoietic stem cell transplantation, 03 medical and health sciences, Myelogenous, Young Adult, 0302 clinical medicine, Bone Marrow, Internal medicine, hemic and lymphatic diseases, medicine, Molecular diagnostics, Humans, Transplantation, Homologous, Cumulative incidence, Remission status, WT1 Proteins, Transplantation, Chemotherapy, Leukemia, business.industry, Minimal residual disease, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, medicine.disease, Flow Cytometry, Prognosis, Survival Analysis, WT1, Leukemia, Myeloid, Acute, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Myelodysplastic Syndromes, Immunology, Female, Bone marrow, business, 030215 immunology
Abstract

The outcome of allogeneic hematopoietic stem cell transplantation (HCT) in patients with myeloid malignancies is better in those without minimal residual disease (MRD) than in those with MRD+, as assessed by multiparametric flow cytometry (MPFC). WT1 quantitation also has been used to assess the probability of relapse in acute myelogenous leukemia (AML) treated with chemotherapy. We analyzed the clinical value of normalized bone marrow WT1 levels as a measure of the expanded myeloid progenitor compartment in a consecutive series of 193 adult patients with myeloid malignancies who underwent HCT. Bone marrow WT1 levels before the HCT, at the first bone marrow aspirate after infusion, and in the follow-up samples after HCT were determined by means of real-time PCR using the European LeukemiaNet normalized method. We sought to clarify the prognostic relevance in terms of overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse (CIR). Based on earlier experience in AML, we selected a threshold of 100 copies, defining 2 groups: patients with 100 copies also included patients who were negative for MRD as assessed by MPFC (19 of 32). During the HCT follow-up, patients with sustained WT1 levels 100 copies (mean, 68 +/- 11 versus 26 +/- 7 days, P < .001; 63 +/- 11 versus 20 +/- 8 days, P < .001; and 20 +/- 8 vs. 71 +/- 8 days, P

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results